High IGF2BP3 Lactylation Levels are Correlated with Poor Therapeutic Responses to Lenvatinib, and Targeting IGF2BP3 Restores the Lenvatinib Response in HCC. This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.